Rewiring Pyroptosis to Potentiate Cancer Immunotherapy via a Gasdermin D Agonist Bypassing Caspase‐3
Advanced Science · 2026
DOI: 10.1002/advs.76655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Dan Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Nanomedicine, College of Life Science and Technology and Key Laboratory of Molecular Biophysics of the Minis…. Hauptthemen laut MEDLINE: Pyroptosis, Caspase 3, Immunotherapy, Phosphate-Binding Proteins. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Double First-class.
Abstract (Originalsprache)
Pyroptosis holds great promise for evoking robust anti‐tumor immunity, but many pyroptosis induction strategies rely on caspase‐3 (Casp‐3) activation and face challenges of the immunosuppressive nature of apoptosis and the frequent silencing of gasdermin E (GSDME), a substrate of Casp‐3, in tumors. Here, we report a strategy to rewire the pyroptotic pathway by bypassing Casp‐3 to directly activate gasdermin D (GSDMD). We identify a small‐molecule agonist, (E)‐2,3‐diiodobut‐2‐ene‐1,4‐diol (DIBDO), which undergoes deiodination to release iodide ions upon activation by the tumor‐abundant nucleophile glutathione, thereby catalytically generating singlet oxygen and molecular iodine. This cascade induces oxidative damage that downregulates key mediators of caspase‐9 and caspase‐8 pathways, thereby down‐regulating Casp‐3 activation. This mechanism selectively triggers GSDMD‐mediated pyroptosis, provoking robust immunogenic cell death and inflammatory cytokine release to reconfigure the tumor immune microenvironment. In murine tumor models, DIBDO enhances tumor infiltration of cytotoxic T cells and synergizes with checkpoint blockade therapy to suppress both primary and distal tumors. It can also serve as an in situ or exogenous vaccine to elicit potent and durable antitumor immunity. This work presents a paradigm‐shifting approach to cancer immunotherapy by decoupling pyroptosis from Casp‐3 dependence, offering a promising avenue to expand the scope of immunogenic cell death‐based treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Research Center for Nanomedicine, College of Life Science and Technology and Key Laboratory of Molecular Biophysics of the Ministry of Education, Huazhong University of Science and Technology, Wuhan…
- Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan, China.
- Hubei Key Laboratory of Bioinformatics and Molecular Imaging, College of Life Science and Technology and Key Laboratory of Molecular Biophysics of the Ministry of Education, Huazhong University of Science and Technology…
ORCID-Profile: Liang Luo
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Double First-class
- "Double First-class" Funds for Central Universities in Hubei
Zitieren
APA
Zhao, D., Zhang, L., Wen, Y., Cheng, L., Tian, S., Meng, F., & Luo, L. (2026). Rewiring Pyroptosis to Potentiate Cancer Immunotherapy via a Gasdermin D Agonist Bypassing Caspase‐3. Advanced Science. https://doi.org/10.1002/advs.76655
Vancouver
Zhao D, Zhang L, Wen Y, Cheng L, Tian S, Meng F, et al. Rewiring Pyroptosis to Potentiate Cancer Immunotherapy via a Gasdermin D Agonist Bypassing Caspase‐3. Advanced Science. 2026. doi:10.1002/advs.76655
BibTeX
@article{Zhao2026,
author = {Zhao, Dan and Zhang, Lingling and Wen, Yue and Cheng, Lianghui and Tian, Sidan and Meng, Fanling and Luo, Liang},
title = {Rewiring Pyroptosis to Potentiate Cancer Immunotherapy via a Gasdermin D Agonist Bypassing Caspase‐3},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76655}
}
EUVIMED